{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:30Z","timestamp":1792047810121,"version":"4.4.0"},"reference-count":198,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"am","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL81326"],"award-info":[{"award-number":["HL81326"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL58837"],"award-info":[{"award-number":["HL58837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL140025"],"award-info":[{"award-number":["HL140025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL101972"],"award-info":[{"award-number":["HL101972"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM116184"],"award-info":[{"award-number":["GM116184"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI088937"],"award-info":[{"award-number":["AI088937"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL101972"],"award-info":[{"award-number":["HL101972"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM116184"],"award-info":[{"award-number":["GM116184"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.blre.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T21:57:45Z","timestamp":1523483865000},"page":"433-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Plasma contact factors as therapeutic targets"],"prefix":"10.1016","volume":"32","author":[{"given":"Benjamin F.","family":"Tillman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-2247","authenticated-orcid":false,"given":"Andras","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen J.T.","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.04.001_bb0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/14779072.2015.1034692","article-title":"Dabigatran for the prevention and treatment of thromboembolic disorders","volume":"13","author":"Enriquez","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.blre.2018.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2018.04.001_bb0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.mcna.2016.03.007","article-title":"Pharmacologic therapies in anticoagulation","volume":"100","author":"Ferreira","year":"2016","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.blre.2018.04.001_bb0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","article-title":"Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants","volume":"118","author":"Chan","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.14714","article-title":"Current challenges and future prospects in oral anticoagulant therapy","volume":"178","author":"Czuprynska","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0030","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1160\/TH14-12-1028","article-title":"Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach","volume":"114","author":"Black","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12959-016-0107-z","article-title":"Management of venous thromboembolism: an update","volume":"14","author":"Piran","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2018.04.001_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2018.04.001_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-0035-1544156","article-title":"Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation","volume":"41","author":"Senoo","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0055","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2018.04.001_bb0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coph.2016.01.008","article-title":"Pharmacogenetics and oral antithrombotic drugs","volume":"27","author":"Baker","year":"2016","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.04.001_bb0065","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1111\/jth.12970","article-title":"New strategies for effective treatment of vitamin K antagonist-associated bleeding","volume":"13","author":"Yates","year":"2015","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.04.001_bb0075","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2018.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1707278","article-title":"Dabigatran reversal with idarucizumab","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0085","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0090","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(15)62056-3","article-title":"PER977 reverses low molecular weight heparin in addition to IIA and XA new oral anticoagulants","volume":"65","author":"Costin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2018.04.001_bb0100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/PPA.S131157","article-title":"Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism","volume":"11","author":"Keita","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2018.04.001_bb0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2018.04.001_bb0125","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2018.04.001_bb0130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2018.04.001_bb0135","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.blre.2018.04.001_bb0140","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","article-title":"Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal","volume":"43","author":"Dowlatshahi","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2018.04.001_bb0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2018.04.001_bb0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmed.2017.00019","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MOH.0000000000000271","article-title":"Antithrombotic potential of the contact activation pathway","volume":"23","author":"Schmaier","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems: pathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0175","series-title":"Rare coagulation factor deficiencies. Hematol. Basic Princ. Pract","first-page":"2034","author":"Gailani","year":"2018"},{"key":"10.1016\/j.blre.2018.04.001_bb0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/asheducation-2014.1.60","article-title":"Recent insights into the role of the contact pathway in thrombo-inflammatory disorders","volume":"2014","author":"van Montfoort","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2018.04.001_bb0185","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2011-10-386185","article-title":"Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis","volume":"119","author":"Tucker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0190","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.cell.2009.11.001","article-title":"Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo","volume":"139","author":"M\u00fcller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.blre.2018.04.001_bb0195","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-07-368811","article-title":"Polyphosphate is a cofactor for the activation of factor XI by thrombin","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.04.001_bb0200","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1111\/jth.12896","article-title":"Polyphosphate as modulator of hemostasis, thrombosis, and inflammation","volume":"13","author":"Morrissey","year":"2015","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0205","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2018.04.001_bb0210","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/ATVBAHA.114.304114","article-title":"Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms","volume":"34","author":"Gould","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2018.04.001_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1160\/TH15-04-0336","article-title":"Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway","volume":"115","author":"Vu","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0220","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1160\/TH16-09-0691","article-title":"Nucleic acids as cofactors for factor XI and prekallikrein activation: different roles for high-molecular-weight kininogen","volume":"117","author":"Ivanov","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2008-07-171066","article-title":"Dual role of collagen in factor XII-dependent thrombus formation","volume":"114","author":"van der Meijden","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0230","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1538-7836.2010.03850.x","article-title":"Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner","volume":"8","author":"White-Adams","year":"2010","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0235","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/ATVBAHA.114.303209","article-title":"Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques","volume":"34","author":"van Montfoort","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2018.04.001_bb0240","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/ATVBAHA.114.303315","article-title":"Factor XII regulates the pathological process of thrombus formation on ruptured plaques","volume":"34","author":"Kuijpers","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2018.04.001_bb0245","first-page":"3208","article-title":"Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation","volume":"118","author":"Maas","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.04.001_bb0250","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1160\/TH07-01-0051","article-title":"The dual role of the contact system in bacterial infectious disease","volume":"98","author":"Frick","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0162-3109(99)00067-3","article-title":"FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery","volume":"45","author":"Wendel","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.blre.2018.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1213\/ANE.0b013e3182354b7e","article-title":"Activation of the hemostatic system during cardiopulmonary bypass","volume":"113","author":"Sniecinski","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.blre.2018.04.001_bb0265","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0270","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1046\/j.1523-1755.2001.00009.x","article-title":"Role of contact system activation in hemodialyzer-induced thrombogenicity","volume":"60","author":"Frank","year":"2001","journal-title":"Kidney Int"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.04.001_bb0275","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0280","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.blre.2018.04.001_bb0285","first-page":"M790","article-title":"Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device","volume":"41","author":"Himmelreich","year":"1995","journal-title":"ASAIO J Am Soc Artif Intern Organs 1992"},{"key":"10.1016\/j.blre.2018.04.001_bb0290","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0295","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2016-10-744110","article-title":"Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation","volume":"129","author":"Ivanov","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0300","article-title":"Proteolytic activity in single-chain prekallikrein","author":"Ivanov","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0305","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1152\/ajpregu.00535.2002","article-title":"The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction","volume":"285","author":"Schmaier","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.blre.2018.04.001_bb0310","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2174\/1566524014666141015153519","article-title":"Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor)","volume":"14","author":"Wang","year":"2014","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0315","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1073\/pnas.022626899","article-title":"Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2018.04.001_bb0320","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaci.2013.03.026","article-title":"Factor XII-independent activation of the bradykinin-forming cascade: implications for the pathogenesis of hereditary angioedema types I and II","volume":"132","author":"Joseph","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2018.04.001_bb0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0330","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0335","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/IAI.00180-15","article-title":"Streptococcus pyogenes triggers activation of the human contact system by streptokinase","volume":"83","author":"Nitzsche","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.blre.2018.04.001_bb0340","doi-asserted-by":"crossref","first-page":"825","DOI":"10.18388\/abp.2015_1142","article-title":"Kinetic and thermodynamic characterization of the interactions between the components of human plasma kinin-forming system and isolated and purified cell wall proteins of Candida albicans","volume":"62","author":"Seweryn","year":"2015","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.blre.2018.04.001_bb0345","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.smim.2016.10.010","article-title":"Blood coagulation in immunothrombosis-at the frontline of intravascular immunity","volume":"28","author":"Gaertner","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.blre.2018.04.001_bb0350","article-title":"Haemostasis and innate immunity - a complementary relationship: a review of the intricate relationship between coagulation and complement pathways","author":"Keragala","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0355","series-title":"Hematology, Basic Principles and Practice","first-page":"2001","article-title":"Hemophilia A and B","volume":"2018","author":"Carcao","year":"2018"},{"key":"10.1016\/j.blre.2018.04.001_bb0360","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why factor XI deficiency is a clinical concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0365","series-title":"Hematology, Basic Principles and Practice","first-page":"1885","article-title":"Molecular basis of blood coagulation","volume":"2018","author":"Brummel-Ziedens","year":"2018"},{"key":"10.1016\/j.blre.2018.04.001_bb0370","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2010.03899.x","article-title":"Coagulation procofactor activation by factor XIa","volume":"8","author":"Whelihan","year":"2010","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0375","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0380","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2014-10-604587","article-title":"Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor","volume":"125","author":"Puy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood-2010-10-312983","article-title":"Activation of factor XI by products of prothrombin activation","volume":"118","author":"Matafonov","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0395","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0400","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/hae.12628","article-title":"Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre","volume":"21","author":"Santoro","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.04.001_bb0405","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","article-title":"Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy","volume":"12","author":"Salomon","year":"2006","journal-title":"Haemophilia"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2018.04.001_bb0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hae.12402","article-title":"Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency","volume":"20","author":"James","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.04.001_bb0415","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V65.3.719.719","article-title":"Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds","volume":"65","author":"Ragni","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0038-1653750","article-title":"Definition of the bleeding tendency in factor XI-deficient kindreds\u2014a clinical and laboratory study","volume":"73","author":"Bolton-Maggs","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/(SICI)1096-8652(199901)60:1<48::AID-AJH8>3.0.CO;2-Q","article-title":"Factor XI deficiency in women","volume":"60","author":"Kadir","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0430","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0435","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0440","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.thromres.2016.02.020","article-title":"A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation","volume":"140","author":"Kokoye","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00003","article-title":"Plasma prekallikrein: its role in hereditary angioedema and health and disease","volume":"5","author":"Schmaier","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0450","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2014-01-550285","article-title":"Reduced thrombosis in Klkb1\u2212\/\u2212 mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor","volume":"125","author":"Stavrou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0455","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"Gruber","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0460","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0465","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0470","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0475","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0480","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1538-7836.2009.03544.x","article-title":"Genetic variants associated with deep vein thrombosis: the F11 locus","volume":"7","author":"Li","year":"2009","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0485","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ajh.24168","article-title":"Prospective study of circulating factor XI and incident venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"90","author":"Folsom","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0490","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0495","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis Basel Switz"},{"key":"10.1016\/j.blre.2018.04.001_bb0500","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.943738","article-title":"Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study","volume":"122","author":"Siegerink","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.04.001_bb0505","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","article-title":"Inherited factor XI deficiency confers no protection against acute myocardial infarction","volume":"1","author":"Salomon","year":"2003","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0510","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0515","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1656366","article-title":"The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and\/or arterial thromboembolism","volume":"68","author":"Halbmayer","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0520","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1055\/s-0037-1614368","article-title":"Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency\u2014a study on 73 subjects from 14 Swiss families","volume":"82","author":"Zeerleder","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0525","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.1994.tb04937.x","article-title":"John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia study","volume":"87","author":"Koster","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0530","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0535","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0540","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2337\/diabetes.52.5.1215","article-title":"Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes","volume":"52","author":"Jaffa","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.blre.2018.04.001_bb0545","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/db15-0930","article-title":"Plasma Prekallikrein is associated with carotid intima-media thickness in type 1 diabetes","volume":"65","author":"Jaffa","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.blre.2018.04.001_bb0550","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0609.2007.00871.x","article-title":"A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region","volume":"79","author":"Katsuda","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12881-016-0283-5","article-title":"Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system","volume":"17","author":"Biswas","year":"2016","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.blre.2018.04.001_bb0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fmed.2016.00017","article-title":"A cross-sectional study of KLKB1 and PRCP polymorphisms in patient samples with cardiovascular disease","volume":"3","author":"Gittleman","year":"2016","journal-title":"Front Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0565","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/all.12587","article-title":"Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk","volume":"70","author":"Reshef","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2018.04.001_bb0570","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood.V82.11.3350.3350","article-title":"Mechanisms of thrombin generation during surgery and cardiopulmonary bypass","volume":"82","author":"Boisclair","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0575","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/026765919901400104","article-title":"Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces","volume":"14","author":"Wendel","year":"1999","journal-title":"Perfusion"},{"key":"10.1016\/j.blre.2018.04.001_bb0580","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0003-4975(00)01404-1","article-title":"Alterations in coagulation after implantation of a pulsatile Novacor LVAD and the axial flow MicroMed DeBakey LVAD","volume":"70","author":"Koster","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.blre.2018.04.001_bb0585","doi-asserted-by":"crossref","DOI":"10.1038\/nrneph.2017.17","article-title":"Cardiovascular disease in haemodialysis: role of the intravascular innate immune system","author":"Ekdahl","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.blre.2018.04.001_bb0590","first-page":"98","article-title":"Antithrombotic factor XI antibody inhibition of the intrinsic pathway","volume":"42a","author":"Gruber","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0595","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0600","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.04.001_bb0605","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.blre.2018.04.001_bb0610","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0615","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0620","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2018.04.001_bb0625","article-title":"Covalent strategies for targeting messenger and non-coding RNAs: an updated review on siRNA, miRNA and antimiR conjugates","volume":"9","author":"Grijalvo","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.blre.2018.04.001_bb0630","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1182\/blood-2012-11-465674","article-title":"Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production","volume":"121","author":"Safdar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0635","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2015-10-672766","article-title":"Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice","volume":"127","author":"Heestermans","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0640","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.V118.21.209.209","article-title":"ISIS-FXIRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0645","first-page":"1116","article-title":"Pharmacokinetics and pharmacodynamics of Ionis-FXIRx, an antisense inhibitor of factor XI, in patients with end-stage renal disease on hemodialysis","volume":"130","author":"Bethune","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0650","unstructured":"A Study of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis - Full Text View, ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03358030 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0655","doi-asserted-by":"crossref","first-page":"29023","DOI":"10.1074\/jbc.271.46.29023","article-title":"Identification of a factor IX binding site on the third apple domain of activated factor XI","volume":"271","author":"Sun","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0660","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2009-02-203604","article-title":"Factor XI contributes to thrombin generation in the absence of factor XII","volume":"114","author":"Kravtsov","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0665","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH13-05-0429","article-title":"Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model","volume":"110","author":"van Montfoort","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0670","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/IAI.05568-11","article-title":"Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis","volume":"80","author":"Luo","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.blre.2018.04.001_bb0675","first-page":"115","article-title":"Inhibition of factor XI activation by factor XIIa blocks coagulopathy and provides organ protection and survival benefit in a Baboon model of S. aureus sepsis","volume":"1","author":"Silasi","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0680","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-012-0186-5","article-title":"Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice","volume":"3","author":"Leung","year":"2012","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0685","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/bloodadvances.2017004879","article-title":"Factor XI contributes to myocardial ischemia-reperfusion injury in mice","volume":"2","author":"Lorentz","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2018.04.001_bb0690","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17460441.2017.1384811","article-title":"Discovery methods of coagulation-inhibiting drugs","volume":"12","author":"G\u00f3mez-Outes","year":"2017","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1016\/j.blre.2018.04.001_bb0695","unstructured":"Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03097341 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0700","unstructured":"Prevention of Thromboembolic Events in Total Knee Replacement Patients - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03393481 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0705","unstructured":"Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03398434 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0710","doi-asserted-by":"crossref","first-page":"353ra112","DOI":"10.1126\/scitranslmed.aaf4331","article-title":"Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis","volume":"8","author":"David","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0715","first-page":"1993","article-title":"Structural basis for activity and specificity of an anticoagulant anti-FXIa monoclonal antibody and a reversal agent","author":"Ely","year":"2018","journal-title":"Struct Lond Engl"},{"key":"10.1016\/j.blre.2018.04.001_bb0720","article-title":"The anti-factor XIa antibody BAY 1213790 is a novel anticoagulant that shows strong antithrombotic efficacy without an increased risk of bleeding in rabbit models","volume":"1","author":"Buchmueller","year":"2017","journal-title":"Res Pr Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0725","first-page":"1","article-title":"First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY 1213790, a full human IgG1 antibody targeting coagulation factor XIa, in healthy young men","author":"Thomas","year":"2017","journal-title":"Res Pr Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0730","unstructured":"A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03276143 (accessed January 3, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0735","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2015-04-641472","article-title":"FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen\/tissue factor surfaces under flow","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0740","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0745","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0750","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0755","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","article-title":"In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa","volume":"40","author":"Wong","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"23","key":"10.1016\/j.blre.2018.04.001_bb0760","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.1021\/acs.jmedchem.7b01171","article-title":"Discovery of a parenteral small molecule coagulation factor XIa inhibitor clinical candidate (BMS-962212)","volume":"60","author":"Pinto","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0765","doi-asserted-by":"crossref","first-page":"ATMP117","DOI":"10.1161\/str.48.suppl_1.tmp117","article-title":"Abstract TMP117: preclinical and early clinical characterization of a parenterally administered direct factor XIa inhibitor","volume":"48","author":"Luettgen","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2018.04.001_bb0770","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.13520","article-title":"First in human study to assess safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects","author":"Perera","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2018.04.001_bb0775","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V124.21.1542.1542","article-title":"Discovery of a novel, potent, selective and injectable small molecule inhibitor of blood coagulation factor XIa, ONO-8610539: in vitro and in vivo pharmacological profiles","volume":"124","author":"Gohda","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0780","first-page":"230","article-title":"Antithrombotic effect of ONO-8610539, a new, potent and selective small molecule factor XIa inhibitor, in a monkey model of ateriovenous shunt","volume":"13","author":"Sakai","year":"2015","journal-title":"Int Soc Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0785","doi-asserted-by":"crossref","first-page":"AWP286","DOI":"10.1161\/str.48.suppl_1.wp286","article-title":"Abstract WP286: ONO-8610539, an injectable small-molecule inhibitor of blood coagulation factor XIa, improves cerebral ischemic injuries associated with photothrombotic occlusion of rabbit middle cerebral artery","volume":"48","author":"Sakimoto","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2018.04.001_bb0790","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1021\/jm060978s","article-title":"Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants","volume":"49","author":"Lin","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0795","author":"Inc"},{"key":"10.1016\/j.blre.2018.04.001_bb0800","author":"Inc"},{"key":"10.1016\/j.blre.2018.04.001_bb0805","unstructured":"To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03224260 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0810","unstructured":"An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants - Full Text View - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03341390 (accessed January 19, 2018), 2018."},{"key":"10.1016\/j.blre.2018.04.001_bb0815","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/jm301338q","article-title":"Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa","volume":"56","author":"Al-Horani","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0820","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.thromres.2015.04.017","article-title":"Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants","volume":"136","author":"Al-Horani","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0825","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0830","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02055-x","article-title":"Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa","volume":"7","author":"Donkor","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2018.04.001_bb0835","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/jth.12302","article-title":"Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer","volume":"11","author":"Woodruff","year":"2013","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0840","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jth.13760","article-title":"A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release","volume":"15","author":"Steen Burrell","year":"2017","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2018.04.001_bb0845","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1126\/science.2111585","article-title":"Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein","volume":"248","author":"Smith","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.blre.2018.04.001_bb0850","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.1073\/pnas.0507798102","article-title":"Protease nexin-2\/amyloid beta-protein precursor limits cerebral thrombosis","volume":"102","author":"Xu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2018.04.001_bb0855","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2012-03-419523","article-title":"The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0860","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0049-3848(00)00245-0","article-title":"Protease nexin-2\/Amyloid beta-protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex","volume":"99","author":"Mahdi","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.04.001_bb0865","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jb\/mvq080","article-title":"Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor","volume":"148","author":"Navaneetham","year":"2010","journal-title":"J Biochem (Tokyo)"},{"key":"10.1016\/j.blre.2018.04.001_bb0870","doi-asserted-by":"crossref","first-page":"31647","DOI":"10.1074\/jbc.M114.569665","article-title":"Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis","volume":"289","author":"Vadivel","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2018.04.001_bb0875","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/jth.13538","article-title":"S2\u2032-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor-2 domain1-wild-type, Leu17Arg-mutant and aprotinin","volume":"14","author":"Vadivel","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0880","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2013-08-517474","article-title":"Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo","volume":"122","author":"Ma","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0885","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.12797","article-title":"Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity","volume":"13","author":"Chen","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0890","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1107\/S0907444912009067","article-title":"The Kazal-type inhibitors infestins 1 and 4 differ in specificity but are similar in three-dimensional structure","volume":"68","author":"Campos","year":"2012","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.blre.2018.04.001_bb0895","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/CIRCULATIONAHA.109.924761","article-title":"Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding","volume":"121","author":"Hagedorn","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.04.001_bb0900","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1160\/TH13-08-0668","article-title":"Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit","volume":"111","author":"Xu","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0905","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.13990","article-title":"FXIIa inhibitor rHA-Infestin-4: safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis","volume":"173","author":"May","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.04.001_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146783","article-title":"The coagulation factor XIIa inhibitor rHA-infestin-4 improves outcome after cerebral ischemia\/reperfusion injury in rats","volume":"11","author":"Krupka","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2018.04.001_bb0915","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/jpet.116.238493","article-title":"Factor XIIa as a novel target for thrombosis: target engagement requirement and efficacy in a rabbit model of microembolic signals","volume":"360","author":"Barbieri","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2018.04.001_bb0920","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5551\/jat.30940","article-title":"Tissue factor and Atherothrombosis","volume":"22","author":"Tatsumi","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.blre.2018.04.001_bb0925","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.blre.2018.04.001_bb0930","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0935","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.blre.2018.04.001_bb0940","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0945","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jama.2017.1371","article-title":"Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation","volume":"317","author":"Xian","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2018.04.001_bb0950","doi-asserted-by":"crossref","unstructured":"Redfors B, Gray WA, Lee RJ, Ellenbogen KA, Bonafede M, Ben-Yehuda O. Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke. JACC Clin Electrophysiol 2017:483.","DOI":"10.1016\/j.jacep.2017.04.024"},{"key":"10.1016\/j.blre.2018.04.001_bb0955","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2009.10.009","article-title":"Excerpts from the US renal data system 2009 annual data report","volume":"55","author":"Collins","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2018.04.001_bb0960","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2002-09-2794","article-title":"Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency","volume":"101","author":"Salomon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.04.001_bb0965","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1160\/TH09-03-0172","article-title":"Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies","volume":"102","author":"Livnat","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.04.001_bb0970","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2516.2011.02525.x","article-title":"The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency","volume":"17","author":"Setty","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.04.001_bb0975","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2516.2006.01276.x","article-title":"An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency","volume":"12","author":"Schulman","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.04.001_bb0980","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/atm.2017.01.03","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)-the perfect storm?","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.blre.2018.04.001_bb0985","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2018.04.001_bb0990","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1830016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1830016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:00Z","timestamp":1759436520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1830016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":198,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0268960X1830016X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.04.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma contact factors as therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}